Screener
Spyre Therapeutics, Inc. SYRE Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Other (expense) income: | ||
| Interest income | 6,995 | 6,493 |
| Other (expense) income, net | (30,359) | 2,286 |
| Total other (expense) income | (23,364) | 8,779 |
| Loss before income tax expense | (69,005) | (44,788) |
| Income tax benefit | — | 15 |
| Net loss | $(69,005) | $(44,773) |
| Net loss per share, basic and diluted, Series A Preferred Stock | $(29.66) | $(23.95) |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s other income (expense)?
- Spyre Therapeutics, Inc. (SYRE) reported other income (expense) of -$23.36M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s other income (expense) changed year-over-year?
- Spyre Therapeutics, Inc.'s other income (expense) decreased by 366.1% year-over-year, from $8.78M to -$23.36M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s other income (expense)?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s other income (expense) has grown at a 320.3% compound annual growth rate (CAGR), from $804K to $59.7M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Spyre Therapeutics, Inc.'s other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude